Safety of Favipiravir for Treatment of COVID-19: Latest Systematic Review

Background: Adverse event studies of favipiravir use in treating COVID-19 have been ongoing since it was established as a treatment option. A better understanding the side effects from recent is important developing and assessing recognition effective treatments for COVID-19. Method: This systematic review based on case reports monotherapy Access to included gained via PubMed, SCOPUS, Science Direct, SpringerLink, MedRxiv. Results: Twelve consisting eight four were reviewed. The most common diarrhea, elevated liver enzyme levels, hyperuricemia. None which significantly different comparison. Currently, various adverse reported such drug fever,acute generalized exanthematous pustulosis (AGEP), transient increase viral load. would mostly be subsided after discontinued.Conclusion: treat caused dose-related changes enzymes, increased level uric acid. There no serious effectscompared other antiviral drugs. To improve efficacy safety therapy, prepare an incidence report events special populations children, pregnant women, patients with organ dysfunction.